Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 5.
doi: 10.1038/s41586-025-09721-5. Online ahead of print.

Atomically accurate de novo design of antibodies with RFdiffusion

Affiliations

Atomically accurate de novo design of antibodies with RFdiffusion

Nathaniel R Bennett et al. Nature. .

Abstract

Despite the central role of antibodies in modern medicine, no method currently exists to design novel, epitope-specific antibodies entirely in silico. Instead, antibody discovery currently relies on immunization, random library screening or the isolation of antibodies directly from patients1. Here we demonstrate that combining computational protein design using a fine-tuned RFdiffusion2 network with yeast display screening enables the de novo generation of antibody variable heavy chains (VHHs), single-chain variable fragments (scFvs) and full antibodies that bind to user-specified epitopes with atomic-level precision. We experimentally characterize VHH binders to four disease-relevant epitopes. Cryo-electron microscopy confirms the binding pose of designed VHHs targeting influenza haemagglutinin and Clostridium difficile toxin B (TcdB). A high-resolution structure of the influenza-targeting VHH confirms atomic accuracy of the designed complementarity-determining regions (CDRs). Although initial computational designs exhibit modest affinity (tens to hundreds of nanomolar Kd), affinity maturation using OrthoRep3 enables production of single-digit nanomolar binders that maintain the intended epitope selectivity. We further demonstrate the de novo design of scFvs to TcdB and a PHOX2B peptide-MHC complex by combining designed heavy-chain and light-chain CDRs. Cryo-electron microscopy confirms the binding pose for two distinct TcdB scFvs, with high-resolution data for one design verifying the atomically accurate design of the conformations of all six CDR loops. Our approach establishes a framework for the computational design, screening and characterization of fully de novo antibodies with atomic-level precision in both structure and epitope targeting.

PubMed Disclaimer

Conflict of interest statement

Competing interests: N.R.B., J.L.W., R.J.R., A.J.B., C.W., P.J.Y.L., B.H. and D.B. are co-inventors on US provisional patent number 63/607,651, which covers the computational antibody design pipeline described here. N.R.B., J.L.W., P.J.Y.L. and B.H. are currently employed by Xaira Therapeutics. N.R.B., J.L.W., P.J.Y.L., B.H., R.J.R., A.J.B. and C.W. have received payments relating to the licensing of the inventions described here to Xaira Therapeutics. C.C.L. is a co-founder of K2 Therapeutics, which uses OrthoRep in antibody engineering and evolution. The other authors declare no competing interests.

Update of

  • Atomically accurate de novo design of antibodies with RFdiffusion.
    Bennett NR, Watson JL, Ragotte RJ, Borst AJ, See DL, Weidle C, Biswas R, Yu Y, Shrock EL, Ault R, Leung PJY, Huang B, Goreshnik I, Tam J, Carr KD, Singer B, Criswell C, Wicky BIM, Vafeados D, Sanchez MG, Kim HM, Torres SV, Chan S, Sun SM, Spear T, Sun Y, O'Reilly K, Maris JM, Sgourakis NG, Melnyk RA, Liu CC, Baker D. Bennett NR, et al. bioRxiv [Preprint]. 2025 Feb 28:2024.03.14.585103. doi: 10.1101/2024.03.14.585103. bioRxiv. 2025. Update in: Nature. 2025 Nov 5. doi: 10.1038/s41586-025-09721-5. PMID: 38562682 Free PMC article. Updated. Preprint.

References

    1. Wilson, P. C. & Andrews, S. F. Tools to therapeutically harness the human antibody response. Nat. Rev. Immunol. 12, 709–719 (2012). - DOI - PubMed - PMC
    1. Watson, J. L. et al. De novo design of protein structure and function with RFdiffusion. Nature 620, 1089–1100 (2023). - DOI - PubMed - PMC
    1. Paulk, A. M., Williams, R. L. & Liu, C. C. Rapidly inducible yeast surface display for antibody evolution with OrthoRep. ACS Synth. Biol. 13, 2629–2634 (2024). - DOI - PubMed
    1. Lyu, X. et al. The global landscape of approved antibody therapies. Antib. Ther. 5, 233–257 (2022). - PubMed - PMC
    1. Sormanni, P., Aprile, F. A. & Vendruscolo, M. Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins. Proc. Natl Acad. Sci. USA 112, 9902–9907 (2015). - DOI - PubMed - PMC

LinkOut - more resources